BioTech 365

JUNE 7, 2021

Applied DNA Reports Veterinary COVID-19 Vaccine Candidate Induces Neutralizing Antibodies in 100% of Trial Cohort Against B.1.1.7, 1.526 Variants and Sets August 2021 Mink Challenge Trial Launch Applied DNA Reports Veterinary COVID-19 Vaccine Candidate Induces Neutralizing Antibodies in … Continue reading →

DNA 52

DNA Antibody Trials Vaccination 52

The Pharma Data

NOVEMBER 26, 2020

26, 2020 /PRNewswire/ — BASE10 Genetics and DNA Link today announced their collaboration on a research project to evaluate the usability of DNA Link ‘ s AccuFind COVID-19 IgG antibody test in a healthcare setting. Study will expand access to antibody testing outside of laboratory settings. DNA Link, Inc.

DNA 52

DNA Antibody Research Genome 52

The Pharma Data

DECEMBER 23, 2020

” Dr. Stanley Plotkin , Professor Emeritus at The Wistar Institute, said, “INOVIO’s DNA vaccine appeared to be quite safe with few significant reactions but yet induced both antibody and T cell responses to SARS-CoV-2.” mg dose group and 84% demonstrating neutralizing antibodies in the 2.0

DNA 40

DNA Vaccination Vaccine Immune Response 40

XTalks

SEPTEMBER 30, 2020

The research shows that the activity of the immune messenger type 1 interferon (IFN) protein is diminished, either by genetic mutations or an autoimmune attack by neutralizing antibodies against it, in a subset of COVID-19 patients. These rogue antibodies blocked interferon action and were not present in patients with mild COVID-19 cases.

Antibody 135

Antibody Genetics Research In-Vitro 135

Pharmaceutical Technology

JUNE 8, 2023

The partnership’s initial focus is to support drug developers to advance cell and gene therapies (CGT) using pioneering modalities including viral vectors (AAV, LVV, RV and HSV), antibodies (mAb, bsAb and ADC), CAR-T therapies and vaccines (DNA, mRNA and protein).

Gene Therapy 130

Gene Therapy Gene Development Antibody 130

pharmaphorum

SEPTEMBER 29, 2020

Inovio Pharma’s plan to start pivotal testing of its COVID-19 vaccine has been delayed by FDA requests for more information, sending its shares into a swift decline. Inovio’s vaccine takes the form of a DNA plasmid coding for the full length of the spike or ‘s’ glycoprotein antigen of SARS-CoV-2, the vaccine that causes COVID-19.

Vaccination 52

Vaccination Vaccine Trials DNA 52

Drug Discovery Today

SEPTEMBER 16, 2021

Demand for Touchlight’s synthetic DNA vector has grown rapidly since last year.dbDNA™ is driving biomedical innovations such as DNA and mRNA vaccines, synthetic DNA-based neutralising antibody therapies, and more.Touchlight’s synthetic DNA vector is revolutionising genetic medicine manufacture by offering a superior alternative to traditional plasmid (..)

DNA 45

DNA Genetics Antibody Manufacturing 45

Pharmaceutical Technology

FEBRUARY 14, 2023

Within the emerging innovation stage, cell therapy for ocular disorders, coronavirus vaccine components, and DNA polymerase compositions are disruptive technologies that are in the early stages of application and should be tracked closely. Vaccination with these peptides is a promising new treatment strategy for chronic HBV.

Antibody 130

Antibody Vaccination Vaccine DNA 130

Pharma Packaging Solutions

JUNE 30, 2023

Whole blood, organ and tissue transplants, breast milk, antibodies for passive immunity, fecal microbiota, human reproductive cells, and stem-cell therapy are all examples of this type of biologic.

Recombinant DNA Technology 52

Recombinant DNA Technology Packaging Packaging Gene Therapy 52

Pharmaceutical Technology

FEBRUARY 15, 2023

Within the emerging innovation stage, cell therapy for ocular disorders, coronavirus vaccine components, and DNA polymerase compositions are disruptive technologies that are in the early stages of application and should be tracked closely.

In-Vivo 162

In-Vivo Genome Genomics Gene Editing 162

Drug Discovery World

NOVEMBER 8, 2022

Mutations have enabled the virus to grow stronger and smarter, evading antiviral drugs and vaccines. . The monkeypox virus is very similar to the vaccinia virus, which has been used as a vaccine to treat smallpox.

Drugs 52

Drugs DNA Vaccination Vaccine 52

Pharmaceutical Technology

FEBRUARY 14, 2023

Within the emerging innovation stage, cell therapy for ocular disorders, coronavirus vaccine components, and DNA polymerase compositions are disruptive technologies that are in the early stages of application and should be tracked closely.

In-Vivo 130

In-Vivo DNA Antibody Gene 130

Drug Discovery World

JUNE 7, 2023

Hosted by DDW and sponsored by DNA Script, join us for this free-to-attend roundtable to learn about the biggest opportunities for the future of drug discovery and development. How important will mRNA-based vaccines be in treating viruses and diseases such as cancer? Is it true that the next era will belong to antibody drug conjugates?

Development 52

Development Gene Therapy Drugs DNA 52

Pharmaceutical Technology

FEBRUARY 14, 2023

Within the emerging innovation stage, cell therapy for ocular disorders, coronavirus vaccine components, and DNA polymerase compositions are disruptive technologies that are in the early stages of application and should be tracked closely.

Antibody 263

Antibody DNA Research Development 263

Drug Discovery World

JUNE 27, 2023

Hosted by DDW and supported by DNA Script, ‘Drug discovery and development trends – what will have most impact?’ How important will mRNA-based vaccines be in treating viruses and diseases such as cancer? Is it true that the next era will belong to antibody drug conjugates?

Drugs 52

Drugs Gene Therapy DNA Antibody 52

Pharmaceutical Technology

FEBRUARY 15, 2023

Within the emerging innovation stage, cell therapy for ocular disorders, coronavirus vaccine components, and DNA polymerase compositions are disruptive technologies that are in the early stages of application and should be tracked closely. In terms of application diversity, Eli Lilly is the top company, followed by C.

Genetics 130

Genetics DNA Antibody Genome 130

Drug Discovery World

JUNE 22, 2023

Hosted by DDW and supported by DNA Script, ‘Drug discovery and development trends – what will have most impact?’ How important will mRNA-based vaccines be in treating viruses and diseases such as cancer? Is it true that the next era will belong to antibody drug conjugates?

Drugs 52

Drugs Gene Therapy DNA Antibody 52

Drug Discovery World

JUNE 15, 2023

Hosted by DDW and sponsored by DNA Script, ‘Drug discovery and development trends – what will have most impact?’ How important will mRNA-based vaccines be in treating viruses and diseases such as cancer? Is it true that the next era will belong to antibody drug conjugates?

Development 52

Development Drugs Gene Therapy DNA 52

Pharmaceutical Technology

FEBRUARY 15, 2023

Within the emerging innovation stage, cell therapy for ocular disorders, coronavirus vaccine components, and DNA polymerase compositions are disruptive technologies that are in the early stages of application and should be tracked closely. IgG antibody responses are a useful marker of antigen exposure to diagnose immunodeficiency.

Gene Expression 130

Gene Expression Gene Genetic Engineering Antibody 130

Drug Discovery World

JUNE 8, 2023

Hosted by DDW and sponsored by DNA Script, ‘Drug discovery and development trends – what will have most impact?’ How important will mRNA-based vaccines be in treating viruses and diseases such as cancer? Is it true that the next era will belong to antibody drug conjugates?

Development 52

Development Drugs Gene Therapy DNA 52

Pharmaceutical Technology

FEBRUARY 14, 2023

Within the emerging innovation stage, cell therapy for ocular disorders, coronavirus vaccine components, and DNA polymerase compositions are disruptive technologies that are in the early stages of application and should be tracked closely.

Antibody 242

Antibody DNA Research Development 242

Pharmaceutical Technology

JUNE 4, 2023

Within the emerging innovation stage, cell therapy for ocular disorders, coronavirus vaccine components, and DNA polymerase compositions are disruptive technologies that are in the early stages of application and should be tracked closely. bluebird bio is also developing drugs based on DNA and retro-virus vectors.

Gene Therapy 246

Gene Therapy DNA Gene Genetics 246

The Pharma Data

AUGUST 6, 2020

We pointed out last week that China was a notable missing element in AstraZeneca’s COVID-19 vaccine strategy, despite being the drugmaker’s second-largest market. The pair will also explore the possibility of producing the vaccine for other markets. The vaccine was moved into phase 2/3 in May. That has changed.

Vaccination 52

Vaccination Vaccine Antibody Licensing 52

Pharmaceutical Technology

MAY 15, 2023

Within the emerging innovation stage, cell therapy for ocular disorders, coronavirus vaccine components, and DNA polymerase compositions are disruptive technologies that are in the early stages of application and should be tracked closely. Peptides have a longer shelf life due to their simplicity and ease of transport.

Antibody 130

Antibody DNA Production Medicine 130

Pharmaceutical Technology

MAY 24, 2023

Within the emerging innovation stage, cell therapy for ocular disorders, coronavirus vaccine components, and DNA polymerase compositions are disruptive technologies that are in the early stages of application and should be tracked closely.

Medicine 130

Medicine Vaccination Vaccine Gene 130

Pharmaceutical Technology

MAY 8, 2023

Within the emerging innovation stage, cell therapy for ocular disorders, coronavirus vaccine components, and DNA polymerase compositions are disruptive technologies that are in the early stages of application and should be tracked closely.

Antibody 147

Antibody Vaccination Vaccine Dermatology 147

Pharmaceutical Technology

MARCH 9, 2023

Within the emerging innovation stage, cell therapy for ocular disorders, coronavirus vaccine components, and DNA polymerase compositions are disruptive technologies that are in the early stages of application and should be tracked closely. Sanofi and F. Hoffmann-La Roche are the other key patent filers in transgenic murine models.

In-Vivo 130

In-Vivo Antibody Genetics Gene 130

Delveinsight

AUGUST 6, 2020

Zydus starts phase 2 COVID-19 vaccine trial after clearing safety test. Zydus Cadila has finished a phase 1 clinical trial of its COVID-19 vaccine ZyCoV-D, setting it up to move straight into a 1,000-subject phase 2 study. ZyCoV-D is designed to introduce DNA that encodes for a viral protein into human cells.

Allergies 53

Allergies Vaccination Vaccine Gene Therapy 53

Pharmaceutical Technology

APRIL 18, 2023

Within the emerging innovation stage, cell therapy for ocular disorders, coronavirus vaccine components, and DNA polymerase compositions are disruptive technologies that are in the early stages of application and should be tracked closely. These can serve as an important component of a vaccine.

Protein 147

Protein Vaccination Vaccine Production 147

Pharmaceutical Technology

MAY 15, 2023

Within the emerging innovation stage, cell therapy for ocular disorders, coronavirus vaccine components, and DNA polymerase compositions are disruptive technologies that are in the early stages of application and should be tracked closely. By means of geographic reach, BioGaia holds the top position.

Drugs 130

Drugs Vaccination Vaccine Antibody 130

Pharmaceutical Technology

JUNE 4, 2023

Within the emerging innovation stage, cell therapy for ocular disorders, coronavirus vaccine components, and DNA polymerase compositions are disruptive technologies that are in the early stages of application and should be tracked closely.

Genetics 130

Genetics Gene Expression DNA Antibody 130

Pharmaceutical Technology

MARCH 9, 2023

Within the emerging innovation stage, cell therapy for ocular disorders, coronavirus vaccine components, and DNA polymerase compositions are disruptive technologies that are in the early stages of application and should be tracked closely.

Antibody 130

Antibody DNA Drugs Development 130

Pharmaceutical Technology

MARCH 9, 2023

Within the emerging innovation stage, cell therapy for ocular disorders, coronavirus vaccine components, and DNA polymerase compositions are disruptive technologies that are in the early stages of application and should be tracked closely.

Protein 130

Protein Antibody DNA Research 130

The Pharma Data

MAY 7, 2021

Pfizer-BioNTech files for US approval of COVID-19 vaccine ( Reuters ) ( NYTimes ) ( Politico ) ( Press ). Covid-19 Vaccines Are Wasted as Special Syringes Run Short ( WSJ ). The US opened pandora’s box on IP waivers for Covid-19 vaccines. . In Focus: US. What happens now?

Vaccination 52

Vaccination Vaccine Drugs Regulation 52

Pharmaceutical Technology

FEBRUARY 14, 2023

Within the emerging innovation stage, cell therapy for ocular disorders, coronavirus vaccine components, and DNA polymerase compositions are disruptive technologies that are in the early stages of application and should be tracked closely.

Antibody 130

Antibody Hormones DNA Licensing 130

Pharmaceutical Technology

FEBRUARY 14, 2023

Within the emerging innovation stage, cell therapy for ocular disorders, coronavirus vaccine components, and DNA polymerase compositions are disruptive technologies that are in the early stages of application and should be tracked closely.

Drugs 130

Drugs Antibody DNA Research 130

Pharmaceutical Technology

MAY 15, 2023

Within the emerging innovation stage, cell therapy for ocular disorders, coronavirus vaccine components, and DNA polymerase compositions are disruptive technologies that are in the early stages of application and should be tracked closely.

Life Science 162

Life Science DNA Antibody Development 162